2
|
Halloum I, Al-Attrache H, El-Ghoz K, Hammoud L, Abdel-Razzak Z. Dose-dependent interaction of two heavy metals with amiodarone toxicity in Saccharomyces cerevisiae. Toxicol Ind Health 2022; 38:249-258. [PMID: 35513769 DOI: 10.1177/07482337221088354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Amiodarone (AMD) is an antiarrhythmic drug that induces idiosyncratic toxicity. Environmental pollutants, including heavy metals, could interact with its toxicity by affecting pharmacokinetics and pharmacodynamics. Other levels of interaction could exist in yeast, such as oxidative stress and the general stress response. In this study, we investigated the interaction of mercury chloride (HgCl2) and cadmium chloride (CdCl2) with AMD toxicity on Saccharomyces cerevisiae. Interaction type - synergistic, additive, or antagonistic - was determined by median drug effect analysis using "CompuSyn". HgCl2 potentiated AMD toxicity at high doses (≥ 71.4 μm, which yielded more than 60% inhibition). CdCl2 acted similarly at high doses (≥ 57.9 μm). An antagonistic effect appeared at lower doses with both heavy metals (≤ 49.4 μm for HgCl2 and AMD; ≤ 18.9 μm for CdCl2 and AMD). The threshold concentrations (HgCl2 or CdCl2 combined with AMD) that switched the interaction from antagonistic to additive, and then to synergistic, were decreased in the yeast strain mutant in catalase (CTT1), suggesting an important role for this enzyme. Moreover, mutation of the nutrient sensing receptor gene GPR1 caused the synergistic interaction of CdCl2, but not HgCl2, with AMD to occur at the lowest tested concentrations (1.2 μm). The reverse was obtained with the mutant strain in calcium-manganese transporter gene PMR1, where the synergistic interaction of HgCl2 with AMD occurred at concentrations (20.7 μm) lower than that of the wild type (71.4 μm). These results demonstrated a dose-dependent interaction between the two heavy metals with AMD toxicity, and the involvement of oxidative stress, calcium homeostasis, and nutrient sensing in the observed interaction.
Collapse
Affiliation(s)
- Iman Halloum
- 63572Lebanese University, FS1, Rafic Hariri Campus, Beirut. Lebanon
| | - Houssein Al-Attrache
- 63572Lebanese University, FS1, Rafic Hariri Campus, Beirut. Lebanon.,Faculty of Sciences, Section III, 63572Lebanese University, Tripoli, Lebanon.,Faculty of Public Health, Section IV, 63572Lebanese University, Zahleh, Lebanon
| | - Katia El-Ghoz
- 63572Lebanese University, FS1, Rafic Hariri Campus, Beirut. Lebanon
| | - Lara Hammoud
- Faculty of Sciences, Section III, 63572Lebanese University, Tripoli, Lebanon
| | - Ziad Abdel-Razzak
- 63572Lebanese University, FS1, Rafic Hariri Campus, Beirut. Lebanon.,EDST, AZM biotechnology research center, LBA3B, Tripoli, Lebanon
| |
Collapse
|
5
|
Bachour-El Azzi P, Sharanek A, Abdel-Razzak Z, Antherieu S, Al-Attrache H, Savary CC, Lepage S, Morel I, Labbe G, Guguen-Guillouzo C, Guillouzo A. Impact of inflammation on chlorpromazine-induced cytotoxicity and cholestatic features in HepaRG cells. Drug Metab Dispos 2014; 42:1556-66. [PMID: 25002748 DOI: 10.1124/dmd.114.058123] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Several factors are thought to be implicated in the occurrence of idiosyncratic adverse drug reactions. The present work aimed to question as to whether inflammation is a determinant factor in hepatic lesions induced by chlorpromazine (CPZ) using the human HepaRG cell line. An inflammation state was induced by a 24-hour exposure to proinflammatory cytokines interleukin-6 (IL-6) and IL-1β; then the cells were simultaneously treated with CPZ and/or cytokine for 24 hours or daily for 5 days. The inflammatory response was assessed by induction of C-reactive protein and IL-8 transcripts and proteins as well as inhibition of CPZ metabolism and down-regulation of cytochrome 3A4 (CYP3A4) and CYP1A2 transcripts, two major cytochrome P450 (P450) enzymes involved in its metabolism. Most effects of cotreatments with cytokines and CPZ were amplified or only observed after five daily treatments; they mainly included increased cytotoxicity and overexpression of oxidative stress-related genes, decreased Na(+)-taurocholate cotransporting polypeptide mRNA levels and activity, a key transporter involved in bile acids uptake, and deregulation of several other transporters. However, CPZ-induced inhibition of taurocholic acid efflux and pericanalicular F-actin distribution were not affected. In addition, a time-dependent induction of phospholipidosis was noticed in CPZ-treated cells, without obvious influence of the inflammatory stress. In summary, our results show that an inflammatory state induced by proinflammatory cytokines increased cytotoxicity and enhanced some cholestatic features induced by the idiosyncratic drug CPZ in HepaRG cells. These changes, together with inhibition of P450 activities, could have important consequences if extrapolated to the in vivo situation.
Collapse
Affiliation(s)
- Pamela Bachour-El Azzi
- Inserm UMR991, Foie, Métabolismes et Cancer, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); Université de Rennes 1, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); EDST-PRASE and EDST-AZM-Center-LBA3B, Université Libanaise, Lebanon (P.B-E.A., H.A-A., Z.A-R.); Laboratoire d'Urgence et de Réanimation, Hôpital Pontchaillou, Rennes, France (S.L., I.M.); Sanofi R&D, Alfortville, France (G.L.)
| | - Ahmad Sharanek
- Inserm UMR991, Foie, Métabolismes et Cancer, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); Université de Rennes 1, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); EDST-PRASE and EDST-AZM-Center-LBA3B, Université Libanaise, Lebanon (P.B-E.A., H.A-A., Z.A-R.); Laboratoire d'Urgence et de Réanimation, Hôpital Pontchaillou, Rennes, France (S.L., I.M.); Sanofi R&D, Alfortville, France (G.L.)
| | - Ziad Abdel-Razzak
- Inserm UMR991, Foie, Métabolismes et Cancer, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); Université de Rennes 1, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); EDST-PRASE and EDST-AZM-Center-LBA3B, Université Libanaise, Lebanon (P.B-E.A., H.A-A., Z.A-R.); Laboratoire d'Urgence et de Réanimation, Hôpital Pontchaillou, Rennes, France (S.L., I.M.); Sanofi R&D, Alfortville, France (G.L.)
| | - Sebastien Antherieu
- Inserm UMR991, Foie, Métabolismes et Cancer, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); Université de Rennes 1, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); EDST-PRASE and EDST-AZM-Center-LBA3B, Université Libanaise, Lebanon (P.B-E.A., H.A-A., Z.A-R.); Laboratoire d'Urgence et de Réanimation, Hôpital Pontchaillou, Rennes, France (S.L., I.M.); Sanofi R&D, Alfortville, France (G.L.)
| | - Houssein Al-Attrache
- Inserm UMR991, Foie, Métabolismes et Cancer, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); Université de Rennes 1, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); EDST-PRASE and EDST-AZM-Center-LBA3B, Université Libanaise, Lebanon (P.B-E.A., H.A-A., Z.A-R.); Laboratoire d'Urgence et de Réanimation, Hôpital Pontchaillou, Rennes, France (S.L., I.M.); Sanofi R&D, Alfortville, France (G.L.)
| | - Camille C Savary
- Inserm UMR991, Foie, Métabolismes et Cancer, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); Université de Rennes 1, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); EDST-PRASE and EDST-AZM-Center-LBA3B, Université Libanaise, Lebanon (P.B-E.A., H.A-A., Z.A-R.); Laboratoire d'Urgence et de Réanimation, Hôpital Pontchaillou, Rennes, France (S.L., I.M.); Sanofi R&D, Alfortville, France (G.L.)
| | - Sylvie Lepage
- Inserm UMR991, Foie, Métabolismes et Cancer, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); Université de Rennes 1, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); EDST-PRASE and EDST-AZM-Center-LBA3B, Université Libanaise, Lebanon (P.B-E.A., H.A-A., Z.A-R.); Laboratoire d'Urgence et de Réanimation, Hôpital Pontchaillou, Rennes, France (S.L., I.M.); Sanofi R&D, Alfortville, France (G.L.)
| | - Isabelle Morel
- Inserm UMR991, Foie, Métabolismes et Cancer, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); Université de Rennes 1, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); EDST-PRASE and EDST-AZM-Center-LBA3B, Université Libanaise, Lebanon (P.B-E.A., H.A-A., Z.A-R.); Laboratoire d'Urgence et de Réanimation, Hôpital Pontchaillou, Rennes, France (S.L., I.M.); Sanofi R&D, Alfortville, France (G.L.)
| | - Gilles Labbe
- Inserm UMR991, Foie, Métabolismes et Cancer, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); Université de Rennes 1, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); EDST-PRASE and EDST-AZM-Center-LBA3B, Université Libanaise, Lebanon (P.B-E.A., H.A-A., Z.A-R.); Laboratoire d'Urgence et de Réanimation, Hôpital Pontchaillou, Rennes, France (S.L., I.M.); Sanofi R&D, Alfortville, France (G.L.)
| | - Christiane Guguen-Guillouzo
- Inserm UMR991, Foie, Métabolismes et Cancer, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); Université de Rennes 1, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); EDST-PRASE and EDST-AZM-Center-LBA3B, Université Libanaise, Lebanon (P.B-E.A., H.A-A., Z.A-R.); Laboratoire d'Urgence et de Réanimation, Hôpital Pontchaillou, Rennes, France (S.L., I.M.); Sanofi R&D, Alfortville, France (G.L.)
| | - André Guillouzo
- Inserm UMR991, Foie, Métabolismes et Cancer, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); Université de Rennes 1, Rennes, France (P.B-E.A., A.S., S.A., H.A-A., C.C.S., I.M., C.G-G., A.G.); EDST-PRASE and EDST-AZM-Center-LBA3B, Université Libanaise, Lebanon (P.B-E.A., H.A-A., Z.A-R.); Laboratoire d'Urgence et de Réanimation, Hôpital Pontchaillou, Rennes, France (S.L., I.M.); Sanofi R&D, Alfortville, France (G.L.)
| |
Collapse
|
6
|
Sharanek A, Azzi PBE, Al-Attrache H, Savary CC, Humbert L, Rainteau D, Guguen-Guillouzo C, Guillouzo A. Different dose-dependent mechanisms are involved in early cyclosporine a-induced cholestatic effects in hepaRG cells. Toxicol Sci 2014; 141:244-53. [PMID: 24973091 DOI: 10.1093/toxsci/kfu122] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Mechanisms involved in drug-induced cholestasis in humans remain poorly understood. Although cyclosporine A (CsA) and tacrolimus (FK506) share similar immunosuppressive properties, only CsA is known to cause dose-dependent cholestasis. Here, we have investigated the mechanisms implicated in early cholestatic effects of CsA using the differentiated human HepaRG cell line. Inhibition of efflux and uptake of taurocholate was evidenced as early as 15 min and 1 h respectively after addition of 10μM CsA; it peaked at around 2 h and was reversible. These early effects were associated with generation of oxidative stress and deregulation of cPKC pathway. At higher CsA concentrations (≥50μM) alterations of efflux and uptake activities were enhanced and became irreversible, pericanalicular F-actin microfilaments were disorganized and bile canaliculi were constricted. These changes were associated with induction of endoplasmic reticulum stress that preceded generation of oxidative stress. Concentration-dependent changes were observed on total bile acid disposition, which were characterized by an increase and a decrease in culture medium and cells, respectively, after a 24-h treatment with CsA. Accordingly, genes encoding hepatobiliary transporters and bile acid synthesis enzymes were differently deregulated depending on CsA concentration. By contrast, FK506 induced limited effects only at 25-50μM and did not alter bile canaliculi. Our data demonstrate involvement of different concentration-dependent mechanisms in CsA-induced cholestasis and point out a critical role of endoplasmic reticulum stress in the occurrence of the major cholestatic features.
Collapse
Affiliation(s)
- Ahmad Sharanek
- Inserm UMR991, Foie, Métabolisme et Cancer, Rennes, France Université de Rennes 1, Rennes, France
| | - Pamela Bachour-El Azzi
- Inserm UMR991, Foie, Métabolisme et Cancer, Rennes, France Université de Rennes 1, Rennes, France
| | - Houssein Al-Attrache
- Inserm UMR991, Foie, Métabolisme et Cancer, Rennes, France Université de Rennes 1, Rennes, France
| | - Camille C Savary
- Inserm UMR991, Foie, Métabolisme et Cancer, Rennes, France Université de Rennes 1, Rennes, France
| | - Lydie Humbert
- ERL Inserm U1157/UMR7203, Faculté de Medecine Pierre et Marie Curie, Site Saint Antoine, Paris, France
| | - Dominique Rainteau
- ERL Inserm U1157/UMR7203, Faculté de Medecine Pierre et Marie Curie, Site Saint Antoine, Paris, France
| | | | - André Guillouzo
- Inserm UMR991, Foie, Métabolisme et Cancer, Rennes, France Université de Rennes 1, Rennes, France
| |
Collapse
|